An irreversible inhibitor of monoamine oxidase types A and B that is used as an antidepressive agent. It has also been used as an antitubercular agent, but its use is limited by its toxicity.
Iproniazid has been studied across 14 research domains including 🌤️ Mood & Depression, 🫁 Liver & Detox, 🧠 Focus & Attention, 🫘 Kidney, ❤️ Cardiovascular. The primary research focus is 🌤️ Mood & Depression with 23% of studies addressing this area.
The following compounds share molecular targets with Iproniazid, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Iproniazid is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.